查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529613

癌症免疫学临床试验市场规模、份额和趋势分析：按阶段、设计、适应症、地区和细分市场预测，2024-2030

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

癌症免疫学临床试验市场成长与趋势：

Grand View Research的最新报告显示，到2030年，全球癌症免疫学临床试验市场规模预计将达到187亿美元。

预计2024年至2030年该市场将以12.1%的复合年增长率扩张。快速发展的免疫肿瘤学领域已成为肿瘤生态系统中的一个新的治疗领域，改变了癌症治疗。

从2014年到2017年，新的免疫肿瘤学研究数量从250项增加到近600项，随着药物类别的多样化，每年以两位数的速度成长。这种快速增长的关键驱动因素是生物标记和查核点抑制剂的测试。儘管免疫肿瘤学市场的多种药理学类别正在日趋成熟，但细胞疗法的成长速度超过了所有其他免疫疗法。截至2020年3月，全球整体癌细胞治疗产品线中有1,483种活性化合物，较2019年3月增加472种。成长最快的类别是嵌合体抗原受体T（CAR-T）细胞产品（2019年至2020年成长77%）。

此外，在COVID-19大流行期间，正在开发的IO药物数量从2019年的3,876种增加到2020年的4,720种，分别比2019年和2017年增加了22%和233%。与 2018 年和 2017 年的 68% 相比，2019 年的 22% 增幅为 15%，这表明，儘管受到 COVID-19 大流行的影响，人们对 IO 的兴趣有所恢復。

癌症免疫学临床试验市场报告亮点

  • 到 2023 年，III 期试验将主导市场，占最大份额，达到 53.2%。肿瘤学临床试验通常参与者较少，费用最高，且样本大小较大，导致每位参与者的成本较高。
  • 2023年介入实验占78.5%以上的市场占有率。
  • 2023年固态肿瘤领域占收益占有率为55.9%。这主要是由于固态肿瘤的盛行率不断增加。
  • 北美地区主导市场，2020 年收益占有率最大，为 50.3%。这是由于越来越多地采用以个人化医疗为重点的新型治疗方法，以及政府的资助和投资。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章癌症免疫学临床试验市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 癌症免疫学临床试验市场分析工具
    • 波特的分析
    • PESTEL分析

第四章癌症免疫学临床试验市场：阶段估计与趋势分析

  • 细分仪表板
  • 癌症免疫学临床试验市场：相变分析，十亿美元，2023-2030

第五章癌症免疫学临床试验市场：设计估算与趋势分析

  • 细分仪表板
  • 癌症免疫学临床试验市场：设计变异分析，十亿美元，2023 年和 2030 年

第六章 癌症免疫学临床试验市场：适应症估计及趋势分析

  • 细分仪表板
  • 癌症免疫学临床试验市场：适应症变异分析，十亿美元，2023 年和 2030 年

第七章癌症免疫学临床试验市场：区域估计与趋势分析

  • 2023 年和 2030 年癌症免疫学临床试验市场占有率（按地区），十亿美元
  • 北美洲
    • 2018-2030年北美癌症免疫学临床试验市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年欧洲癌症免疫学临床试验市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030年亚太地区癌症免疫学临床试验市场估计与预测
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 2018-2030年拉丁美洲癌症免疫学临床试验市场估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018-2030年中东与非洲癌症免疫学临床试验市场估计与预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • MEDPACE
    • Novartis
    • Exscientia
    • Syneous Health
    • AstraZeneca
    • IQ BIOTECH
    • BioNtech
    • IQVIA Holdings
    • ICON, Plc
    • Laboratory Corporation of America Holdings
简介目录
Product Code: GVR-4-68038-273-0

Immuno-oncology Clinical Trials Market Growth & Trends:

The global immuno-oncology clinical trials market size is expected to reach USD 18.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2024 to 2030. The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.

From 2014 to 2017, the number of new immuno-oncology studies increased from 250 to almost 600, with double-digit growth rates each year as drug classes diversified. Biomarker and checkpoint inhibitor studies were primarily responsible for this rapid growth. While the immuno-oncology market is maturing in some pharmacological classes, cell therapies are exceeding all other immunotherapeutics in terms of growth. In March 2020, there were 1,483 active compounds in the pipeline for cancer cell therapy globally, indicating an increase of 472 from March 2019. The fastest-growing category was chimeric antigen receptor T (CAR-T) cell products (up 77% from 2019 to 2020).

Besides, during the Covid-19 pandemic, the number of IO drugs in development increased from 3,876 in 2019 to 4,720 in 2020, representing a 22% & 233% increase as compared to 2019 & 2017 respectively. After a moderate increase of 15% in 2019 compared to 68% between 2018 and 2017, this 22% increase indicates a return of interest in IO, despite the impact of the COVID-19 pandemic.

Immuno-oncology Clinical Trials Market Report Highlights:

  • Phase III dominated the market with the largest share of 53.2% in 2023. Oncology trials typically have fewer participants, are the most expensive, and involve larger sample sizes, resulting in a higher cost per participant.
  • The interventional experiments accounted for more than 78.5% of the market share in 2023
  • The segment of solid tumors held 55.9% of the revenue share in 2023. This is largely attributed to the rise in the prevalence of solid tumors
  • North America dominated the market and accounted for the largest revenue share of 50.3% in 2020. This is due to the rising adoption of personalized medicine-focused novel treatment methods, as well as the government funding and investments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Immuno-oncology Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Immuno-oncology Clinical Trials Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Immuno-oncology Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Immuno-oncology Clinical Trials Market: Phase Movement Analysis, USD Billion, 2023 & 2030
    • 4.2.1. Phase I
      • 4.2.1.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.2. Phase II
      • 4.2.2.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.3. Phase III
      • 4.2.3.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 4.2.4. Phase IV
      • 4.2.4.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Immuno-oncology Clinical Trials Market: Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Immuno-oncology Clinical Trials Market: Design Movement Analysis, USD Billion, 2023 & 2030
    • 5.2.1. Interventional Trials
      • 5.2.1.1. Interventional Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.2.2. Observational Trials
      • 5.2.2.1. Observational Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 5.2.3. Expanded Access Trials
      • 5.2.3.1. Expanded Access Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Immuno-oncology Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Immuno-oncology Clinical Trials Market: Indication Movement Analysis, USD Billion, 2023 & 2030
    • 6.2.1. Solid Tumors
      • 6.2.1.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 6.2.2. Hematological Cancer Healthcare
      • 6.2.2.1. Hematological Cancer Healthcare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Immuno-oncology Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Immuno-oncology Clinical Trials Market Share, By Region, 2023 & 2030, USD Billion
  • 7.2. North America
    • 7.2.1. North America Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. UK
      • 7.3.2.1. U.K. Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. MEDPACE
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. Novartis
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. Exscientia
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Syneous Health
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. AstraZeneca
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. IQ BIOTECH
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. BioNtech
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. IQVIA Holdings
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. ICON, Plc
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Laboratory Corporation of America Holdings
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives